Ronan O’Hagan - President & CEO, Bectas Therapeutics Inc.

Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc.  Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval.

 

• Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval.
• His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves.
• O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute.
• He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry.
• O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.